CAL
FATE icon

Capital Advisors Ltd’s Fate Therapeutics FATE Stock Holding History

Capital Advisors Ltd’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed – – 1339
2022
Q3 		$0 Buy
+7
New +$202 ﹤0.01% 1312
2022
Q2 		– Sell
-7
Closed – – 1092
2022
Q1 		$0 Buy
+7
New +$271 ﹤0.01% 995

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Advisors Ltd's FATE Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 7 shares.

Capital Advisors Ltd first reported a position in FATE in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 7 Fate Therapeutics shares in Q4 2022.
  • Capital Advisors Ltd first reported a position in Fate Therapeutics in Q1 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Fate Therapeutics position peaked at $0 in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.